ReviewBreathe (Sheffield, England)2025
Nasal nitric oxide measurement for the diagnosis of primary ciliary dyskinesia: summary of the European Respiratory Society technical standard.
Review in Breathe (Sheffield, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nasal nitric oxide combined with clinical features for preliminary screening of primary ciliary dyskinesia in bronchiectasis.The European respiratory journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasal nitric oxide (nNO) measurement is important in the primary ciliary dyskinesia (PCD) diagnostic pathway because levels are consistently very low in most patients. Machine type, environmental factors, respiratory manoeuvres and report interpretation are fundamental considerations when performing nNO testing. A European Respiratory Society Task Force recently published standards for testing which we summarise and discuss in this article. There are two main types of nNO machines: chemiluminescence and electrochemical analysers. Chemiluminescence analysers are highly accurate, reliable, real-time and have been validated in multicentre studies but are less portable and more expensive to purchase and maintain in comparison to electrochemical devices. Several factors may influence nNO levels and need to be addressed during patient preparation for testing. Factors including acute viral infections and nose bleeds may contribute to falsely low nNO levels, whereas high ambient NO levels may falsely increase nNO. Tidal breathing, breath-hold and exhalation against resistance are the three main respiratory manoeuvres used in nNO sampling and require a minimal, modest and high level of patient cooperation respectively. Finally, standardised reporting of nNO testing and the correct interpretation helps clinicians to formulate an appropriate clinical plan towards an accurate PCD diagnosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.